FACS analyses revealed that 89.2 and 82.1 % of the resulting Hep3B-TRCs and PLC/PRF/5-TRCs, respectively, were enriched for the expression of EpCAM+ and CD133+, two surface antigens that mark the stemness of HCC stem cells [13] (Figure S2a, b). The gene discussed is EPCAM; the disease is hepatocellular carcinoma.